Bimatoprost and travoprost: A review of recent studies of two new glaucoma drugs

被引：90

作者：

Eisenberg, DL

Toris, CB

Camras, CB

机构：

[1] Shepherd Eye Ctr, Las Vegas, NV USA

[2] Univ Nebraska, Med Ctr 985145, Dept Ophthalmol, Omaha, NE 68198 USA

来源：

SURVEY OF OPHTHALMOLOGY | 2002年 / 47卷

关键词：

bimatoprost; glaucoma; intraocular pressure; ocular hypertension; latanoprost; timolol; travoprost;

D O I：

10.1016/S0039-6257(02)00327-2

中图分类号：

R77 [眼科学];

学科分类号：

100212 ;

摘要：

Bimatoprost (Lumigan(TM) [Allergan, Inc, Irvine GA]) and travoprost (Travatan(TM) [Alcon, Ft Worth, TX]) are two new intraocular pressure (IOP)-lowering drugs for use in patients with glaucoma and ocular hypertension. This review evaluates recent studies comparing these new drugs with timolol and with latanoprost. In each study, the statistical analyses support the conclusion that these agents were more effective than timolol and as effective as latanoprost in terms of their ability to reduce IOP. The side effect profiles for bimatoprost, latanoprost, and travoprost were similar, but with statistically higher occurrences of hyperemia and eyelash growth for bimatoprost or travoprost versus latanoprost or timolol.

引用

收藏

页码：S105 / S115

页数：11

相关论文

共 52 条

[1] PHXA34, A NEW POTENT OCULAR HYPOTENSIVE DRUG - A STUDY ON DOSE-RESPONSE RELATIONSHIP AND ON AQUEOUS-HUMOR DYNAMICS IN HEALTHY-VOLUNTEERS [J].

ALM, A ;

VILLUMSEN, J .

ARCHIVES OF OPHTHALMOLOGY, 1991, 109 (11) :1564-1568

[2] Phase III latanoprost studies in Scandinavia, the United Kingdom and the United States [J].

Alm, A ;

Camras, CB ;

Watson, PG .

SURVEY OF OPHTHALMOLOGY, 1997, 41 :S105-S110

[3] Effects on intraocular pressure and side effects of 0.005% latanoprost applied once daily, evening or morning - A comparison with timolol [J].

Alm, A ;

Stjernschantz, J ;

Widengard, I ;

Linden, C ;

Soderstrom, M ;

Nilsson, SE ;

Fristrom, B ;

Lindblom, B ;

Heijl, A ;

Gundersen, KG ;

Ehinger, B ;

Holmin, C ;

BengtssonStigmar, E ;

Aasved, H ;

Jangard, P ;

Ringvold, A ;

Vegge, T ;

Halseide, R ;

LundAndersen, H ;

Flesner, P ;

Thygesen, J ;

Airaksinen, J ;

Tuulonen, A .

OPHTHALMOLOGY, 1995, 102 (12) :1743-1752

[4]

[Anonymous], 1989, STAT BIOL

[5] Comparison of once- or twice-daily bimatoprost with twice-daily timolol in patients with elevated IOP -: A 3-month clinical trial [J].

Brandt, JD ;

VanDenburgh, AM ;

Chen, K ;

Whitcup, SM .

OPHTHALMOLOGY, 2001, 108 (06) :1023-1031

[6] Effects of AGN 192024, a new ocular hypotensive agent, on aqueous dynamics [J].

Brubaker, RF ;

Schoff, EO ;

Nau, CB ;

Carpenter, SP ;

Chen, KK ;

Vandenburgh, AM .

AMERICAN JOURNAL OF OPHTHALMOLOGY, 2001, 131 (01) :19-24

[7] Latanoprost treatment for glaucoma: Effects of treating for 1 year and of switching from timolol [J].

Camras, CB ;

Wax, MB ;

Ritch, R ;

Weinreb, R ;

Robin, AL ;

Higginbotham, EJ ;

Lustgarten, J ;

Stewart, WC ;

Sherwood, M ;

Krupin, T ;

Wilensky, J ;

Cioffi, GA ;

Katz, LJ ;

Schumer, RA ;

Kaufman, PL ;

Minckler, D ;

Zimmerman, T ;

Stjernschantz, J .

AMERICAN JOURNAL OF OPHTHALMOLOGY, 1998, 126 (03) :390-399

[8]

Camras CB, 2002, AM J OPHTHALMOL, V133, P732, DOI 10.1016/S0002-9394(02)01396-X

[9] Bimatoprost vs. timolol [J].

Camras, CB .

OPHTHALMOLOGY, 2002, 109 (04) :627-628

[10] Does that drug work? Pitfalls in studies on the efficacy and safety of glaucoma medications [J].

Camras, CB ;

Minckler, D .

AMERICAN JOURNAL OF OPHTHALMOLOGY, 2000, 129 (01) :87-89

← 1 2 3 4 5 6 →